Cargando…

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for advanced lung adenocarcinoma. The patient was admitted to our hospital due to non-bloody watery diarrhea after the 70th dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yasuda, Yuichiro, Urata, Yoshiko, Tohnai, Rie, Ito, Shoichi, Kawa, Yoshitaka, Kono, Yuko, Hattori, Yoshihiro, Tsuda, Masahiro, Sakuma, Toshiko, Negoro, Shunichi, Satouchi, Miyako
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980808/ https://www.ncbi.nlm.nih.gov/pubmed/29279482 http://dx.doi.org/10.2169/internalmedicine.9230-17

Ejemplares similares

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
por: Hattori, Yoshihiro, et al.
Publicado: (2020)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
por: Sueoka‐Aragane, Naoko, et al.
Publicado: (2016)

Nivolumab and immune‐mediated colitis
por: Walker, Heather, et al.
Publicado: (2019)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review
por: Nishiyama, Akihiro, et al.
Publicado: (2021)

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
por: Katsuya, Yuki, et al.
Publicado: (2023)

Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer
por: Fukuda, Kiyoko, et al.
Publicado: (2023)

Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma
por: Fujii, Yosuke, et al.
Publicado: (2017)

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
por: Hida, Toyoaki, et al.
Publicado: (2017)

Remission of ulcerative colitis flare-up induced by nivolumab
por: Iwamoto, Maho, et al.
Publicado: (2020)

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2017)

Role of S1P/S1PR3 axis in release of CCL20 from human bronchial epithelial cells
por: Kawa, Yoshitaka, et al.
Publicado: (2018)

Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
por: Anson, David, et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
por: Hijikata, Yasuki, et al.
Publicado: (2020)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
por: Yamauchi, Ryosuke, et al.
Publicado: (2018)

Nivolumab-Induced Colitis in a Patient With Esophageal Adenocarcinoma: A Case Report
por: Vlachos, Iakovos, et al.
Publicado: (2023)

The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer
por: Takegawa, Naoki, et al.
Publicado: (2023)

Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
por: Nassri, Ammar B, et al.
Publicado: (2019)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018)

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA
por: John, Thomas, et al.
Publicado: (2022)

Infliximab recovers central cone dysfunction with normal fundus in a patient with ulcerative colitis
por: Chiba-Mayumi, Miyako, et al.
Publicado: (2021)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report
por: Fukuda, Yuko, et al.
Publicado: (2022)

Intestinal Tuberculosis with Hoarseness as a Chief Complaint due to Mediastinal Lymphadenitis
por: Nagai, Kenta, et al.
Publicado: (2011)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer
por: Tokuyama, Nagahiro, et al.
Publicado: (2021)

Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)
por: Udagawa, Hibiki, et al.
Publicado: (2021)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

An autopsy case of immune-related severe colitis due to long-term use of nivolumab in a patient with non-small cell lung cancer
por: Fujikawa, Masashi, et al.
Publicado: (2022)

Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2022)

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
por: Kobayashi, Tomoko, et al.
Publicado: (2018)

Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials
por: Nagano, Tatsuya, et al.
Publicado: (2019)

Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases
por: Yamasaki, Masahiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kc5c1j0tgd6q1m7fvcf7q66cjt